Developer docs
API playgroundTry for free, no card

Search company profiles

Lhasa Limited

Full company profile

uuid000b93j

Namestring
Lhasa Limited
Legal namestring
Lhasa Limited
Company typeenum
Private
Founded yearint
1983
Descriptiontext

Lhasa Limited is a UK-registered charity (no. 290866) founded in 1983 and headquartered in Leeds, operating as a not-for-profit membership organisation that develops in silico software for chemical safety assessment. The company serves pharmaceutical, cosmetics, agrochemical, and medical device manufacturers, with top-20 pharmaceutical companies participating as both members and data contributors to its consortium-based knowledge base. Its technology portfolio comprises nine integrated products — Derek Nexus, Sarah Nexus, Vitic, Meteor, Kaptis, Acrostic, Mirabilis, Zeneth, and LCDB Plus — covering mutagenicity, carcinogenicity, metabolism, impurity, and skin sensitisation assessment, all aligned with major regulatory frameworks (ICH M7, ICH Q3A/B, ICH Q3E, REACH, ISO 10993).

The company's underlying technology combines knowledge-based expert systems, statistical (Q)SAR models, and curated toxicity databases containing over 30,000 peer-reviewed records across 22,000+ substances. Pre-competitive data sharing consortiums (aromatic amines, elemental impurities, complex nitrosamines, excipients, intermediates, organosilicons) enable members to contribute and access proprietary experimental data, creating a collaborative data flywheel. Distribution is direct enterprise sales via annual membership licensing, supplemented by training, technical support, and a scientific marketing program spanning publications, webinars, symposia, and regulatory engagement.

Revenue mechanics are membership-based annual licensing with quote-based pricing (not publicly disclosed). The company reinvests proceeds into software development and collaborative research rather than distributing profit, consistent with its charitable mission. Recent inorganic activity includes the January 2025 acquisitions of Molecular Networks GmbH and Altamira, both undisclosed, signalling expansion of computational chemistry and molecular modelling capabilities beyond the legacy toxicology core.

Short descriptiontext

Lhasa Limited is a UK-registered charity (founded 1983) that develops in silico software for chemical safety assessment, serving pharmaceutical, cosmetics, agrochemical, and medical device manufacturers via a membership-based licensing model anchored by curated toxicity databases and pre-competitive data sharing consortiums.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLeeds, United Kingdom
HQ citystring
Leeds
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational toxicology software, chemical safety assessment, in silico prediction, QSAR mutagenicity prediction, carcinogenicity assessment
Industry5 codes
PRIMARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGADAJ
Elemental Impurities & Trace Metals (ICP-MS)
SECONDARYEUAHABAE
Chemical Management & Toxic Substances Compliance (TSCA, REACH, GHS/SDS, PFAS Programs)
Energy, Utilities & Environment/Environmental Compliance, Monitoring & Consulting/Regulatory Compliance & Auditing (Air, Water, Waste)
SECONDARYHLAGAFAB
Safety Pharmacology (Cardio/CNS/Respiratory)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Computational Toxicology Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Membership-based Software Licensing
TypeSubscription Recurring
Description

Lhasa operates as a not-for-profit membership organisation offering annual software licensing agreements. Members gain access to in silico solutions, curated toxicity databases, and participation in pre-competitive data sharing initiatives. Solution benefits are accessible to members through separate licensing of Lhasa Limited solutions.

lhasalimited.org
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1Annual membership licensing
ModelSubscriptionBilling cadenceAnnual
Notes

Membership-based annual licensing model. Specific pricing tiers and fee structures are not publicly disclosed on the website.

lhasalimited.org
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 9 records shown
1Derek Nexus
Description

Expert knowledge-based software for in silico mutagenicity assessment using (Q)SAR predictions.

lhasalimited.org
+8 more records
Core offering1 text field

Lhasa Limited develops and licenses in silico scientific software for chemical safety decision-making, including knowledge-based (Q)SAR prediction tools (Derek Nexus, Sarah Nexus), curated toxicity databases (Vitic, LCDB Plus), metabolism prediction software (Meteor), guided carcinogenicity decision support (Kaptis), and read-across platforms for nitrosamine and extractables/leachables risk assessment (Acrostic, Mirabilis, Zeneth). Its solutions are licensed to pharmaceutical, cosmetics, agrochemical, and medical device companies to support regulatory submissions under ICH M7, ICH Q3A/B, ICH Q3E, REACH, and ISO 10993 frameworks.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Acrostic read-across tool demonstrates up to 90% time savings compared to fully manual read-across workflows
+4 more records
Product overview1 text field

Lhasa Limited provides a suite of in silico scientific software solutions for chemical safety assessment, organized around two main pillars: (1) Software Solutions including Derek Nexus and Sarah Nexus for in silico mutagenicity assessment, Vitic as a toxicity database, Meteor for metabolism prediction, Kaptis for carcinogenicity assessment, Acrostic for read-across, and Zeneth and Mirabilis for nitrosamine risk assessment; and (2) Data Sharing initiatives enabling precompetitive data exchange across pharmaceutical, chemical, and consumer product industries. The products are delivered as both desktop software and cloud-based membership access, with solutions addressing regulatory compliance requirements including ICH M7, ICH Q3A/B, REACH, and emerging ICH Q3E guidelines.

Product and service9 records
1Derek Nexus
CategoryIn silico mutagenicity assessment
Description

Expert knowledge-based (Q)SAR software for predicting mutagenicity of chemical compounds, providing clear mechanistic rationales and literature-derived evidence for every prediction, used by pharmaceutical and chemical safety scientists to support ICH M7 regulatory submissions.

2Sarah Nexus
CategoryIn silico mutagenicity assessment
Description

Statistical machine learning (Q)SAR prediction tool for mutagenicity assessment, providing complementary predictions to Derek Nexus for comprehensive in silico mutagenicity evaluation and ICH M7 submissions.

3Vitic
CategoryToxicity database
Description

Expert-curated chemical toxicity database offering structure-based searches and rapid access to over 30,000 peer-reviewed toxicity records spanning carcinogenicity, genotoxicity, and skin sensitisation endpoints across 22,000+ substances.

4Meteor
CategoryMetabolism prediction
Description

Knowledge-based expert system for metabolism prediction and metabolite identification (MetID), providing mechanistic rationales and literature-derived evidence for biotransformation predictions, supporting ICH M7, ICH M3 (MIST), ICH Q3A&B and REACH guidelines.

5Kaptis
CategoryCarcinogenicity assessment
Description

Guided decision support software for carcinogenicity assessment, providing structured question-based workflows with confidence scoring and transparent scientific rationales to support defensible safety decisions.

6Acrostic
CategoryRead-across risk assessment
Description

In silico read-across solution for nitrosamine impurity and extractables and leachables (E&L) risk assessment, providing curated datasets, structured workflows, and expert-led scientific logic to support defensible safety decisions with up to 90% time savings.

7Zeneth
CategoryNitrosamine impurity risk assessment
Description

Software solution for nitrosamine impurity risk assessment in pharmaceutical development, supporting safety profiling workflows for impurities and degradants.

8Mirabilis
CategoryNitrosamine impurity risk assessment
Description

In silico tool for monitoring and predicting the risk of nitrosamine impurity formation and assessing toxicological concern in pharmaceutical products.

9LCDB Plus
CategoryCarcinogenicity database
Description

Specialised Lhasa Carcinogenicity Database providing curated carcinogenicity data for chemical safety risk assessment decision-making, used as a knowledge source for carcinogenicity workflows.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Contributed expertise to Lhasa's collaborative whitepaper on implementing the UK Government strategy for replacing animals in science. Participated in a cross-sector roundtable convened by Lhasa addressing NAMs adoption in safety assessment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Contributed executive perspective (Dr Anthony Lynch, Executive Director of Genetic and Investigative Toxicology) to Lhasa's UK NAMs strategy whitepaper roundtable, providing industry insights on NAMs adoption.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Contributed senior perspective (Dr Charlie Stevenson, Senior Chemicals Regulatory Advisor) to Lhasa's collaborative whitepaper on replacing animals in science, representing the animal welfare NGO perspective on NAMs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Participated in Lhasa's cross-sector roundtable contributing expertise on consumer product safety and NAMs adoption across chemical safety assessment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Contributed to Lhasa's UK NAMs strategy whitepaper roundtable, providing research funding and 3Rs expertise perspective on replacing animals in science.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Participated in Lhasa's cross-sector roundtable bringing contract research organisation (CRO) perspective on NAMs implementation in safety assessment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Contributed to Lhasa's UK NAMs strategy whitepaper roundtable representing agrochemical industry perspective on non-animal approach adoption.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Participated in Lhasa's cross-sector roundtable providing academic research perspective on NAMs validation and qualification.

9Kirkland Consulting
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Contributed genetic toxicology consulting expertise to Lhasa's roundtable on implementing UK NAMs strategy.

lhasalimited.org
Strategic tierCoreTypeOthers
Description

Lhasa solutions are aligned with regulatory guidance from EPA, FDA, EMA, and other international regulatory bodies. Regulatory pressures from these bodies are identified as key drivers in the computational toxicology market. Vitic data is accessed by regulatory bodies for validation purposes.

11Data Sharing Consortium Members
Strategic tierCoreTypeOthers
Description

Lhasa facilitates pre-competitive data sharing consortiums including aromatic amines, elemental impurities (ICH Q3D), complex nitrosamines, nitrite impurities, excipients, and FDA RCA initiatives. Consortium members contribute and access high-quality experimental data.

lhasalimited.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MultiCASE is a long-standing direct competitor providing knowledge-based (Q)SAR expert systems (CASE Ultra, META Ultra) for mutagenicity, carcinogenicity, and other toxicology endpoints — the closest analogue to Derek Nexus in approach and customer base.

TypeBroad incumbent
Description

Inotiv is a preclinical CRO with computational toxicology and study management software. It competes with Lhasa in parts of the chemical safety assessment workflow while serving a much broader drug development customer base.

TypeOthers
Description

ChemAxon provides cheminformatics toolkits and software components used widely in drug discovery and chemical safety workflows. It is adjacent infrastructure that overlaps with parts of Lhasa's portfolio following the Molecular Networks acquisition.

TypeDirect peer
Description

Simulations Plus offers ADMET predictor software and Tox/Sim solutions that compete directly with Lhasa's Derek Nexus, Sarah Nexus, and Meteor for in silico ADMET and metabolite prediction across pharma and chemical safety customers.

TypeBroad incumbent
Description

Schrödinger is a broader computational chemistry and materials platform that includes toxicity and ADMET prediction capabilities. It is a much larger, publicly traded incumbent that overlaps with Lhasa's pharma safety assessment use cases as part of a wider portfolio.

TypeBroad incumbent
Description

BIOVIA from Dassault Systèmes is a broad scientific software platform that includes molecular modelling, registration, and safety assessment tools used by large pharma. It is an incumbent competitor in adjacent parts of Lhasa's chemical safety workflow.

TypeDirect peer
Description

Instem acquired Leadscope, which provides in silico toxicology software (Leadscope Model Applier, Genetox) directly competing with Derek Nexus and Sarah Nexus. Both serve pharma and chemical safety assessment with (Q)SAR and expert-rule-based prediction systems.

TypeEmerging player
Description

MolPort provides chemical sourcing and cheminformatics infrastructure used in compound safety evaluation workflows. It overlaps with parts of Lhasa's portfolio following the Molecular Networks and Altamira acquisitions.

TypeEmerging player
Description

Deciphex's Patholytix division applies digital pathology and AI to toxicology and drug safety. It overlaps with Lhasa's safety assessment focus but addresses histopathology rather than in silico (Q)SAR prediction.

TypeEmerging player
Description

Scitovation is a non-profit scientific organisation focused on advancing computational toxicology and NAMs. It is structurally comparable to Lhasa as a mission-driven non-profit working in the same in silico safety assessment space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lhasa Limited

Computational Toxicology Softwarelhasalimited.org

Lhasa Limited is a UK-registered charity (founded 1983) that develops in silico software for chemical safety assessment, serving pharmaceutical, cosmetics, agrochemical, and medical device manufacturers via a membership-based licensing model anchored by curated toxicity databases and pre-competitive data sharing consortiums.

What Lhasa Limited does

Lhasa Limited is a UK-registered charity (no. 290866) founded in 1983 and headquartered in Leeds, operating as a not-for-profit membership organisation that develops in silico software for chemical safety assessment. The company serves pharmaceutical, cosmetics, agrochemical, and medical device manufacturers, with top-20 pharmaceutical companies participating as both members and data contributors to its consortium-based knowledge base. Its technology portfolio comprises nine integrated products — Derek Nexus, Sarah Nexus, Vitic, Meteor, Kaptis, Acrostic, Mirabilis, Zeneth, and LCDB Plus — covering mutagenicity, carcinogenicity, metabolism, impurity, and skin sensitisation assessment, all aligned with major regulatory frameworks (ICH M7, ICH Q3A/B, ICH Q3E, REACH, ISO 10993).

The company's underlying technology combines knowledge-based expert systems, statistical (Q)SAR models, and curated toxicity databases containing over 30,000 peer-reviewed records across 22,000+ substances. Pre-competitive data sharing consortiums (aromatic amines, elemental impurities, complex nitrosamines, excipients, intermediates, organosilicons) enable members to contribute and access proprietary experimental data, creating a collaborative data flywheel. Distribution is direct enterprise sales via annual membership licensing, supplemented by training, technical support, and a scientific marketing program spanning publications, webinars, symposia, and regulatory engagement.

Revenue mechanics are membership-based annual licensing with quote-based pricing (not publicly disclosed). The company reinvests proceeds into software development and collaborative research rather than distributing profit, consistent with its charitable mission. Recent inorganic activity includes the January 2025 acquisitions of Molecular Networks GmbH and Altamira, both undisclosed, signalling expansion of computational chemistry and molecular modelling capabilities beyond the legacy toxicology core.

Lhasa Limited firmographics

Firmographics
Name
Lhasa Limited
Legal name
Lhasa Limited
Website
https://lhasalimited.org
Company type
Private
Founded year
1983
Operating status
Operating
Headcount range
101–250 employees
Short description
Lhasa Limited is a UK-registered charity (founded 1983) that develops in silico software for chemical safety assessment, serving pharmaceutical, cosmetics, agrochemical, and medical device manufacturers via a membership-based licensing model anchored by curated toxicity databases and pre-competitive data sharing consortiums.
Ownership category
akta.pro rank

Lhasa Limited industry classification

Industry
Product category
Computational Toxicology Software
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGADAJ
Elemental Impurities & Trace Metals (ICP-MS)
SECONDARYEUAHABAE
Chemical Management & Toxic Substances Compliance (TSCA, REACH, GHS/SDS, PFAS Programs)
Energy, Utilities & Environment/Environmental Compliance, Monitoring & Consulting/Regulatory Compliance & Auditing (Air, Water, Waste)
SECONDARYHLAGAFAB
Safety Pharmacology (Cardio/CNS/Respiratory)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Computational toxicology software
  • Chemical safety assessment
  • In silico prediction
  • QSAR mutagenicity prediction
  • Carcinogenicity assessment

Where Lhasa Limited is headquartered

Location

Headquarters

HQ city
Leeds
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Lhasa Limited business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Membership-based Software Licensing: Lhasa operates as a not-for-profit membership organisation offering annual software licensing agreements. Members gain access to in silico solutions, curated toxicity databases, and participation in pre-competitive data sharing initiatives. Solution benefits are accessible to members through separate licensing of Lhasa Limited solutions.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualAnnual membership licensing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

Lhasa Limited product offering

Product offering

Core offering

Lhasa Limited develops and licenses in silico scientific software for chemical safety decision-making, including knowledge-based (Q)SAR prediction tools (Derek Nexus, Sarah Nexus), curated toxicity databases (Vitic, LCDB Plus), metabolism prediction software (Meteor), guided carcinogenicity decision support (Kaptis), and read-across platforms for nitrosamine and extractables/leachables risk assessment (Acrostic, Mirabilis, Zeneth). Its solutions are licensed to pharmaceutical, cosmetics, agrochemical, and medical device companies to support regulatory submissions under ICH M7, ICH Q3A/B, ICH Q3E, REACH, and ISO 10993 frameworks.

Product overview

Lhasa Limited provides a suite of in silico scientific software solutions for chemical safety assessment, organized around two main pillars: (1) Software Solutions including Derek Nexus and Sarah Nexus for in silico mutagenicity assessment, Vitic as a toxicity database, Meteor for metabolism prediction, Kaptis for carcinogenicity assessment, Acrostic for read-across, and Zeneth and Mirabilis for nitrosamine risk assessment; and (2) Data Sharing initiatives enabling precompetitive data exchange across pharmaceutical, chemical, and consumer product industries. The products are delivered as both desktop software and cloud-based membership access, with solutions addressing regulatory compliance requirements including ICH M7, ICH Q3A/B, REACH, and emerging ICH Q3E guidelines.

Differentiator

Problem solved

Functional benefit

Brands

  • Derek Nexus: Expert knowledge-based software for in silico mutagenicity assessment using (Q)SAR predictions.
  • Sarah Nexus
  • Kaptis
  • Vitic
  • Meteor
  • Acrostic
  • Mirabilis
  • Zeneth
  • LCDB Plus

Products and services

  • Derek Nexus Expert knowledge-based (Q)SAR software for predicting mutagenicity of chemical compounds, providing clear mechanistic rationales and literature-derived evidence for every prediction, used by pharmaceutical and chemical safety scientists to support ICH M7 regulatory submissions.
  • Sarah Nexus Statistical machine learning (Q)SAR prediction tool for mutagenicity assessment, providing complementary predictions to Derek Nexus for comprehensive in silico mutagenicity evaluation and ICH M7 submissions.
  • Vitic Expert-curated chemical toxicity database offering structure-based searches and rapid access to over 30,000 peer-reviewed toxicity records spanning carcinogenicity, genotoxicity, and skin sensitisation endpoints across 22,000+ substances.
  • Meteor Knowledge-based expert system for metabolism prediction and metabolite identification (MetID), providing mechanistic rationales and literature-derived evidence for biotransformation predictions, supporting ICH M7, ICH M3 (MIST), ICH Q3A&B and REACH guidelines.
  • Kaptis Guided decision support software for carcinogenicity assessment, providing structured question-based workflows with confidence scoring and transparent scientific rationales to support defensible safety decisions.
  • Acrostic In silico read-across solution for nitrosamine impurity and extractables and leachables (E&L) risk assessment, providing curated datasets, structured workflows, and expert-led scientific logic to support defensible safety decisions with up to 90% time savings.
  • Zeneth Software solution for nitrosamine impurity risk assessment in pharmaceutical development, supporting safety profiling workflows for impurities and degradants.
  • Mirabilis In silico tool for monitoring and predicting the risk of nitrosamine impurity formation and assessing toxicological concern in pharmaceutical products.
  • LCDB Plus Specialised Lhasa Carcinogenicity Database providing curated carcinogenicity data for chemical safety risk assessment decision-making, used as a knowledge source for carcinogenicity workflows.

Quantifiable outcome

  • Acrostic read-across tool demonstrates up to 90% time savings compared to fully manual read-across workflows
  • +4 more outcomes

Companies that use Lhasa Limited

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Lhasa Limited technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature9 records

Lhasa Limited partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core.

  • AstraZenecacoreStrategic or Co-development PartnerContributed expertise to Lhasa's collaborative whitepaper on implementing the UK Government strategy for replacing animals in science. Participated in a cross-sector roundtable convened by Lhasa addressing NAMs adoption in safety assessment.
  • GlaxoSmithKlinecoreStrategic or Co-development PartnerContributed executive perspective (Dr Anthony Lynch, Executive Director of Genetic and Investigative Toxicology) to Lhasa's UK NAMs strategy whitepaper roundtable, providing industry insights on NAMs adoption.
  • Cruelty Free InternationalcoreStrategic or Co-development PartnerContributed senior perspective (Dr Charlie Stevenson, Senior Chemicals Regulatory Advisor) to Lhasa's collaborative whitepaper on replacing animals in science, representing the animal welfare NGO perspective on NAMs.
  • UnilevercoreStrategic or Co-development PartnerParticipated in Lhasa's cross-sector roundtable contributing expertise on consumer product safety and NAMs adoption across chemical safety assessment.
  • NC3Rs (National Centre for the Replacement, Refinement & Reduction of Animals in Research)coreStrategic or Co-development PartnerContributed to Lhasa's UK NAMs strategy whitepaper roundtable, providing research funding and 3Rs expertise perspective on replacing animals in science.
  • LabcorpcoreStrategic or Co-development PartnerParticipated in Lhasa's cross-sector roundtable bringing contract research organisation (CRO) perspective on NAMs implementation in safety assessment.
  • SyngentacoreStrategic or Co-development PartnerContributed to Lhasa's UK NAMs strategy whitepaper roundtable representing agrochemical industry perspective on non-animal approach adoption.
  • Liverpool John Moores UniversitycoreStrategic or Co-development PartnerParticipated in Lhasa's cross-sector roundtable providing academic research perspective on NAMs validation and qualification.
  • Kirkland ConsultingcoreStrategic or Co-development PartnerContributed genetic toxicology consulting expertise to Lhasa's roundtable on implementing UK NAMs strategy.
  • Global Regulatory Bodies (EPA, FDA, EMA)coreOthersLhasa solutions are aligned with regulatory guidance from EPA, FDA, EMA, and other international regulatory bodies. Regulatory pressures from these bodies are identified as key drivers in the computational toxicology market. Vitic data is accessed by regulatory bodies for validation purposes.
  • Data Sharing Consortium MemberscoreOthersLhasa facilitates pre-competitive data sharing consortiums including aromatic amines, elemental impurities (ICH Q3D), complex nitrosamines, nitrite impurities, excipients, and FDA RCA initiatives. Consortium members contribute and access high-quality experimental data.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Lhasa Limited competitors and assessment

Company assessment

Direct peers

  • MultiCASE (CASE): MultiCASE is a long-standing direct competitor providing knowledge-based (Q)SAR expert systems (CASE Ultra, META Ultra) for mutagenicity, carcinogenicity, and other toxicology endpoints — the closest analogue to Derek Nexus in approach and customer base.
  • Simulations Plus: Simulations Plus offers ADMET predictor software and Tox/Sim solutions that compete directly with Lhasa's Derek Nexus, Sarah Nexus, and Meteor for in silico ADMET and metabolite prediction across pharma and chemical safety customers.
  • Instem (Leadscope): Instem acquired Leadscope, which provides in silico toxicology software (Leadscope Model Applier, Genetox) directly competing with Derek Nexus and Sarah Nexus. Both serve pharma and chemical safety assessment with (Q)SAR and expert-rule-based prediction systems.

Broad incumbents

  • Inotiv: Inotiv is a preclinical CRO with computational toxicology and study management software. It competes with Lhasa in parts of the chemical safety assessment workflow while serving a much broader drug development customer base.
  • Schrödinger: Schrödinger is a broader computational chemistry and materials platform that includes toxicity and ADMET prediction capabilities. It is a much larger, publicly traded incumbent that overlaps with Lhasa's pharma safety assessment use cases as part of a wider portfolio.
  • Biovia (Dassault Systèmes): BIOVIA from Dassault Systèmes is a broad scientific software platform that includes molecular modelling, registration, and safety assessment tools used by large pharma. It is an incumbent competitor in adjacent parts of Lhasa's chemical safety workflow.

Others

  • ChemAxon: ChemAxon provides cheminformatics toolkits and software components used widely in drug discovery and chemical safety workflows. It is adjacent infrastructure that overlaps with parts of Lhasa's portfolio following the Molecular Networks acquisition.

Emerging players

  • MolPort (cheminformatics): MolPort provides chemical sourcing and cheminformatics infrastructure used in compound safety evaluation workflows. It overlaps with parts of Lhasa's portfolio following the Molecular Networks and Altamira acquisitions.
  • Deciphex (Patholytix): Deciphex's Patholytix division applies digital pathology and AI to toxicology and drug safety. It overlaps with Lhasa's safety assessment focus but addresses histopathology rather than in silico (Q)SAR prediction.
  • Scitovation: Scitovation is a non-profit scientific organisation focused on advancing computational toxicology and NAMs. It is structurally comparable to Lhasa as a mission-driven non-profit working in the same in silico safety assessment space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Lhasa Limited social profiles

Digital presence

Lhasa Limited financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lhasa Limited leadership team

Management profile

Number of profiles

Profiles4 records

Lhasa Limited funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lhasa Limited M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lhasa Limited

What does Lhasa Limited do?

Lhasa Limited develops and licenses in silico scientific software for chemical safety decision-making, including knowledge-based (Q)SAR prediction tools (Derek Nexus, Sarah Nexus), curated toxicity databases (Vitic, LCDB Plus), metabolism prediction software (Meteor), guided carcinogenicity decision support (Kaptis), and read-across platforms for nitrosamine and extractables/leachables risk assessment (Acrostic, Mirabilis, Zeneth). Its solutions are licensed to pharmaceutical, cosmetics, agrochemical, and medical device companies to support regulatory submissions under ICH M7, ICH Q3A/B, ICH Q3E, REACH, and ISO 10993 frameworks.

Is Lhasa Limited a public or private company?

Lhasa Limited is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Lhasa Limited founded?

Lhasa Limited was founded in 1983. It employs 101 to 250 people.

Where is Lhasa Limited based?

Lhasa Limited is headquartered in Leeds, United Kingdom, in the Europe region.

How does Lhasa Limited make money?

One revenue line is on record: membership-based Software Licensing.

Who are Lhasa Limited's main competitors?

Direct peers on record are MultiCASE (CASE), Simulations Plus and Instem (Leadscope). Broad incumbents are Inotiv, Schrödinger and Biovia (Dassault Systèmes). ChemAxon is listed as an others. Emerging players are MolPort (cheminformatics), Deciphex (Patholytix) and Scitovation.

Does Lhasa Limited have an API?

No public API is recorded for Lhasa Limited.

What industry is Lhasa Limited in?

Lhasa Limited's product category is Computational Toxicology Software. Its primary akta.pro industry code is HLAGAFAM, In Silico / Computational Toxicology & PK/PD Modeling, with a secondary code of HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketintellixIn-Depth Research on Computational Toxicology Solutions MarketMarket IntelliX published a market research report projecting the global Computational Toxicology Solutions market to grow from US$54.2 million in 2025 to US$98 million by 2031, representing a CAGR of 10.6% during the forecast period. The report identifies regulatory pressures from bodies such as EPA, FDA, and REACH, advancements in AI and machine learning, and cost-effectiveness compared to traditional in vivo testing as key market drivers. Key players analyzed include Instem (Leadscope), Lhasa Limited, MultiCASE, Inotiv, Simulations Plus Inc, Schrodinger, Aclaris, Evogene, Deciphex (Patholytix), and Exscientia across North America, Europe, Asia-Pacific, South America, and Middle East & Africa regions.PharmiWeb.comLhasa Limited acquires Molecular Networks and Altamira, leaders in chemoinformaticsLhasa Limited, a UK not-for-profit, acquired Molecular Networks and Altamira, chemoinformatics leaders. The acquisitions expand chemical safety assessment offerings, with ChemTunes·ToxGPS used in cosmetics. Lhasa CEO Chris Barber said the move supports its charitable purpose of advancing chemical safety science.PR NewswireLhasa Limited Releases New Data into its Carcinogenicity DatabaseLhasa Limited has released new data into its Carcinogenicity Database (LCDB), incorporating 197 new chemical structures assessed for carcinogenicity by the NTP since 2007. The organization also generated TD50 values for this data to support chemical risk assessments and acceptable limit calculations. This update builds upon the previously retired Carcinogenic Potency Database, ensuring continued access to vital long-term study data.PR NewswireFirst Biotech Member Realises the Benefits of Vitic Through SaaS in the Lhasa CloudLhasa Limited, an educational charity providing in silico prediction and database systems, announced that Idorsia Pharmaceuticals Ltd has become the first organization to adopt its Vitic chemical database through Software as a Service (SaaS) on the Amazon Web Services (AWS) cloud platform. The SaaS deployment eliminates the need for customer installation, additional servers, or hardware while maintaining confidentiality of proprietary information. Idorsia, headquartered in Switzerland and listed on the SIX Swiss Exchange, specializes in small molecule discovery and development, and will benefit from immediate access to Vitic's toxicological data without software maintenance concerns.BusinessCloudExcitement builds for Leeds Digital Job Fair 2.0Leeds Digital Job Fair 2.0 will feature nearly 50 exhibitors at the First Direct Arena on October 20th, including Lhasa Limited, Sky, and Google. Organiser Amy De-Balsi expects around 2,000 attendees, up from 1,300 at the February event. The fair aims to fill digital and tech vacancies in the Leeds region.PR NewswireLhasa Limited receives a Queen's Award for Enterprise for InnovationLhasa Limited, a Yorkshire-based scientific software developer, received the Queen's Award for Enterprise for Innovation in 2016. The award recognizes its Derek Nexus software for predicting chemical toxicity, which has been used since 2010. The award will be presented by the Lord-Lieutenant of West Yorkshire later this year.PR NewswireLhasa Limited Announces the Launch of the Vitic Intermediates DatabaseLhasa Limited announced the latest release of the Vitic Intermediates database, a cross-industry data-sharing consortium. The database now contains 1,088 structures with 16,971 genetic toxicity in-vitro records, supporting ICH M7 guideline compliance. The consortium, initiated in 2006, is in its 9th year and continues to grow.